Lu, Ting
Ma, Rui
Dong, Wenjuan
Teng, Kun-Yu
Kollath, Daniel S.
Li, Zhiyao
Yi, Jinhee
Bustillos, Christian
Ma, Shoubao
Tian, Lei
Mansour, Anthony G.
Li, Zhenlong
Settles, Erik W. http://orcid.org/0000-0003-4331-3683
Zhang, Jianying
Keim, Paul S. http://orcid.org/0000-0003-0089-5820
Barker, Bridget M. http://orcid.org/0000-0002-3439-4517
Caligiuri, Michael A. http://orcid.org/0000-0002-4095-3020
Yu, Jianhua http://orcid.org/0000-0002-0326-3223
Funding for this research was provided by:
Flinn Foundation (2304, 2304)
Arizona Board of Regents
Foundation for the National Institutes of Health (R35CA210087, R01CA068458, P01CA163205, R01NS106170, R01AI129582, R01CA247550, R21CA223400)
California Institute for Regenerative Medicine (DISC2COVID19-11947)
Leukemia and Lymphoma Society (1364-19)
Article History
Received: 22 June 2021
Accepted: 20 April 2022
First Online: 11 May 2022
Competing interests
: Drs. Caligiuri and Yu are co-founders of CytoImmune Therapeutics, Inc. The remaining authors have no conflicts of interest to disclose.